-
Approaches to Model Patient And Carer Utilities and Disutilities of Adverse Events in Economic Models for Rare Disease Treatments in NICE Appraisals
Mar 10, 2025, 14:00 PM -
Understanding Japanese Subsidy Initiatives for Rare, Intractable Diseases
Mar 10, 2025, 14:00 PM -
Demographic Characteristics, Utilization Trends, and Access to GLP-1 Agonists Among Adults in a Nationally Representative Pharmacy Database
Mar 10, 2025, 14:00 PM -
Real-World Adherence, Healthcare Resource Utilization, And Costs Among Patients With Schizophrenia Utilizing Once-Monthly, Once-Every-Three-Months, And Once-Every-Six-Months Paliperidone Palmitate in the United States
Mar 10, 2025, 14:00 PM -
Evaluating the Cost-Effectiveness of Polygenic Risk Score-Guided Breast Cancer Screening Using a Discrete Event Simulation Model
Mar 10, 2025, 14:00 PM -
Trends In Oral JAK Inhibitor And Other Drug Use For Myelofibrosis: A Retrospective Real-World Study
Mar 10, 2025, 14:00 PM -
Evaluating Thresholds for Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures (PROMs) in Locally Advanced or Metastatic Urothelial Cancer (la/mUC): a Systematic Literature Review (SLR)
Mar 10, 2025, 14:00 PM -
Clinical Trial Participant and Clinician Experience in a Phase 2 (US-only) Trial of MM120 for Generalized Anxiety Disorder
Mar 10, 2025, 14:00 PM -
Evaluating the Influence of User-Complexity on Individual Preferences for Upper Limb Prosthetic Selection: Measurement Tool Development for a Discrete Choice Experiment
Mar 10, 2025, 14:00 PM -
Analysis of Patient-Reported Outcomes of MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE)
Mar 10, 2025, 14:00 PM -
Impacts of the Inflation Reduction Act on 2025 Formulary Coverage in Medicare Part D Plans
Mar 10, 2025, 14:00 PM -
Discordance Between Apolipoprotein B (apoB) and LDL-Cholesterol (LDL-C) and Incident Hypertension Risk among Patients with and without Type 2 Diabetes (T2D): An Analysis of US Real-World Data
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Umeclidinium/Vilanterol Combination Therapy for Group B COPD Patients
Mar 10, 2025, 14:00 PM -
Improving the Healthcare System Through Health Technology Assessment: A Case Study of Nepal
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy for Treatment-Naive Patients of Extensive-Stage Small Cell Lung Cancer without Brain Metastasis
Mar 10, 2025, 14:00 PM -
Evaluation of the Cost of Treatment on Endometriosis in the Hungarian Public-Funded Healthcare System
Mar 10, 2025, 14:00 PM -
Evaluating the ROI of a Virtual Maternity Care Initiative Across Medicaid Plans in a Single State
Mar 10, 2025, 14:00 PM -
Keeping With the Times: Emerging Methods for More Precise Survival Estimates to Inform Cost-Effectiveness Analysis
Mar 10, 2025, 14:00 PM -
Comparative Effectiveness and Safety of Factor Xa Inhibitors in Atrial Fibrillation: A Systematic Literature Review of Real-World Evidence in Europe
Mar 10, 2025, 14:00 PM -
Real-World Demographic and Clinical Characteristics of Patients With Atherosclerotic Cardiovascular Disease With or Without Chronic Kidney Disease or Systemic Inflammation in the United States
Mar 10, 2025, 14:00 PM